SCHEMBL297624

SCHEMBL297624

Nc1ccccc1C(=O)NO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.59
GAA P10253 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MPO P05164 1/20 0.59
HIF1A Q16665 1/20 0.59
ALDH1A1 P00352 7/20 0.55
HSD17B10 Q99714 3/20 0.55
CFTR P13569 1/20 0.55
HDAC8 Q9BY41 2/20 0.53
MMP3 P08254 1/20 0.53
FADS1 O60427 1/20 0.53
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
HPGD P15428 3/20 0.50
PTGS1 P23219 1/20 0.50
P2RX1 P51575 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463616 1.00 KDM4E (0.59) KDM4EGAASMN1; SMN2MPOHIF1A
Iodobenzene SCHEMBL27496777 0.89 KDM4E (0.49) KDM4EGAASMN1; SMN2MPOHIF1A
SCHEMBL9921278 0.84 KDM4E (0.60) KDM4EGAASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL1331243 0.83 GAA (0.73) KDM4EGAASMN1; SMN2MPOHIF1A
SCHEMBL11293418 0.83 KDM4E (0.50) KDM4EGAASMN1; SMN2MPOHIF1A
SCHEMBL112991 0.82 ALDH1A1 (0.55) KDM4EGAAALDH1A1HSD17B10CFTR
SCHEMBL27859247 0.81 MMP2 (0.62) KDM4EGAASMN1; SMN2MPOHIF1A
SCHEMBL5245919 0.81 HDAC1 (0.61) KDM4EGAASMN1; SMN2MPOHIF1A
SCHEMBL16677840 0.80 ALDH1A1 (0.53) KDM4EGAASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL8302862 0.80 ALDH1A1 (0.53) KDM4EGAASMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176819-B Method for preparing 3, 6-dihydro-1, 2-oxazine derivative by iodine catalysis in aqueous phase 山东第二医科大学 2025-02-14 CN claimed
CN-119176819-A Method for preparing 3, 6-dihydro-1, 2-oxazine derivative by iodine catalysis in aqueous phase 山东第二医科大学 2024-12-24 CN claimed
US-20240319601-A1 METHOD OF FORMING PATTERNS SAMSUNG SDI CO., LTD. (KR) 2024-09-26 US claimed
CN-117597628-A Method for forming pattern 三星SDI株式会社 2024-02-23 CN claimed
US-20240019784-A1 METAL CONTAINING PHOTORESIST DEVELOPER COMPOSITION, AND METHOD OF FORMING PATTERNS INCLUDING STEP OF DEVELOPING USING THE COMPOSITION SAMSUNG SDI CO., LTD. (KR) 2024-01-18 US claimed
CN-117348341-A Metal-containing photoresist developer composition and pattern forming method 三星SDI株式会社 2024-01-05 CN claimed
CN-115703845-A Oligosaccharide linker and side chain hydrophilic fragment combined sugar chain site-directed antibody-drug conjugate, preparation method and application thereof 中国科学院上海药物研究所 2023-02-17 CN claimed
WO-2023003215-A1 METHOD OF FORMING PATTERNS 삼성에스디아이 주식회사 2023-01-26 WO claimed
CN-113416989-B Silver plating process and silver plated part 苏州瑞港环保科技有限公司 2022-11-01 CN claimed
CN-113416989-A Silver plating process and silver plated part 苏州瑞港环保科技有限公司 2021-09-21 CN claimed
EP-1461010-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS Integriderm, Inc. (US) 2004-09-29 EP claimed
US-20030199558-A1 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners INTEGRIDERM, INC. 2003-10-23 US claimed
WO-2003057184-A2 HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS INTEGRIDERM, INC. (US) 2003-07-17 WO claimed
WO-1992016200-A1 THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT VIRAL REPLICATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1992-10-01 WO claimed
CN-119176819-B Method for preparing 3, 6-dihydro-1, 2-oxazine derivative by iodine catalysis in aqueous phase 山东第二医科大学 2025-02-14 CN disclosed
CN-119176819-A Method for preparing 3, 6-dihydro-1, 2-oxazine derivative by iodine catalysis in aqueous phase 山东第二医科大学 2024-12-24 CN disclosed
US-20240319601-A1 METHOD OF FORMING PATTERNS SAMSUNG SDI CO., LTD. (KR) 2024-09-26 US disclosed
EP-0073912-A1 Oxo-quinazoline-(thiono)-phosphoric(phosphonic)-acid esters or amides, process for their preparation and their use as pesticides BAYER AG (DE) 1983-03-16 EP disclosed
US-4359476-A Adjacently substituted cycloalkane-amide analgesics THE UPJOHN COMPANY (US) 1982-11-16 US disclosed
US-3978208-A ACETOHYDROXAMIC ACID EISAI CO., LTD. (JA) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199558-A1 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners TYR, MC1R, MITF KDM4E 2107/4885GAA 22/4885SMN1; SMN2 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.